Amendments for: 230-2021-2022-Q4-031

Current (Mar 30, 2022)
Agreement Value: $200,000,000.00
Agreement: Medicago Inc. COVID-19 (815733). Oct 18, 2020 - Mar 31, 2024

The project is in direct response to the global fight against COVID-19. The project will be undertaken in two stages: (1) develop a plant-derived virus-like particle (VLP) vaccine for the prevention of COVID-19; and (2) establish a large-scale Good Manufacturing Practice (GMP) Facility for vaccine and antibody production in Canada.

Expected Results:

The direct and immediate benefit of the project's first stage is the rapid development of a plant-based vaccine that may lead to an effective vaccine for COVID-19. The second stage, building a GMP facility that can manufacture vaccine and antibodies, is expected to increase biomanufacturing capabilities and build on areas of strength and technological advantage to advance Canada’s life sciences industry. This project anticipates to maintain 275 full-time jobs and to create 75 full-time jobs within Canada.

Organization: Innovation, Science and Economic Development Canada
Recipient: Medicago inc. (For-profit organization)
Location: Quebec, Quebec, CA G1V3V9
Type: Contribution
Additional Information:

The amendment has been completed to increase the contribution amount from $173M to $200M. This is a partially repayable contribution.

Recipient's Operating Name: Medicago inc.
Federal Riding Name: Louis-Hébert (24044)
Program Name: SIF Stream3- Attraction

The Strategic Innovation Fund (SIF) attracts and supports new high-quality business investments. In allocating funding, SIF looks to accelerate areas of economic strength, strengthen and expand the role of Canadian firms in regional and global supply chains, support economic strategies, and attract investment that creates new, good, well-paying jobs.